Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $40.12 million versus the consensus estimate of $49.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.